Johnson & Johnson (JNJ) Financial Statements

Johnson & Johnson (JNJ) reported trailing twelve-month revenue of $99.3B (up 7.8% year on year) and net income of $16.1B as of 2026-09-27, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $20.6B.

Source: SEC EDGAR filings · figures as of 2026-09-27 · read by EquiReason

JNJJohnson & JohnsonFollow JNJ — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 635.1B
P/E TTM: 40.0
Dividend yield: 2.0%
52-week: —
Next earnings: 26 Jan, in 94 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Sep 26.

Line	FY2018 Dec 18	FY2019 Dec 19	FY2020 Jan 21	FY2021 Jan 22	FY2022 Jan 23	FY2023 Dec 23	FY2024 Dec 24	FY2025 Dec 25	TTM Sep 26
Revenue	81.58	82.06	82.58	78.74	79.99	85.16	88.82	94.19	99.34
Gross profit	54.49	54.50	54.16	55.34	55.39	58.61	61.35	63.94	67.11
Research & development	10.78	11.36	12.16	14.28	14.14	0.48	1.84	0.11	—
Pre-tax income	18.00	17.33	16.50	19.18	19.36	15.06	16.69	32.58	17.74
Income tax	2.70	2.21	1.78	1.38	2.99	1.74	2.62	5.78	1.64
Net income	15.30	15.12	14.71	20.88	17.94	35.15	14.07	26.80	16.10
Diluted EPS ($)	5.61	5.63	5.51	7.81	6.73	13.72	5.79	11.03	6.59
Diluted shares (bn)	2.729	2.684	2.671	2.674	2.664	2.560	2.429	2.429	—

USD billions · SEC XBRL

Johnson & Johnson — questions

What is Johnson & Johnson's revenue?: $99.3B over the twelve months to 2026-09-27, up 7.8% year on year, from its 10-Q and 10-K filings.
What is Johnson & Johnson's net income?: $16.1B over the twelve months to 2026-09-27.
What is Johnson & Johnson's free cash flow?: $20.6B over the twelve months to 2026-09-27.
What are Johnson & Johnson's diluted earnings per share?: $6.59 over the twelve months to 2026-09-27.

Every figure on this page comes from Johnson & Johnson's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.